skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration

What will happen when there is a dispute over which risk class a product falls into under the future Medical Device and IVD Regulations? How does the scrutiny process differ for medical devices and IVDs? Here we detail chapter V of the future regulations, which addresses these and other classification and conformity-assessment issues.

 

Rules_Regulation_Medtech_Insight

 

Once the risk class for a product is known and the relevant basic conformity-assessment procedures applied, there are a series of additional requirements that devices must meet under the forthcoming EU Medical Devices Regulation (MDR) and IVD Regulation (IVDR) that become more involved as the risk inherent in a device rises.

 

Chapter V of the regulations, likely to be adopted in the first quarter of 2017, deals with the scrutiny mechanism for the higher-risk products. This is a mechanism that will allow additional scrutiny by authorities, including the potential for review by an EU-appointed expert panel, of procedures and checks that have already been carried out by the notified body in its review of a product.

 

And for products that come under the scope of the MDR, there is an additional layer of review that comes before the formal scrutiny mechanism kicks in, involving an expert panel reviewing the clinical evaluation work of both the manufacturer and the notified body (NB).

 

Chapter V describes these procedures, along with other conformity-related issues. This table analyzes provisions that are common to both the IVDR and the MDR, and then addresses issues specific to medical devices alone or to IVDs alone.

 

 

Chapter V summary: scrutiny and conformity assessments

 

Chapter-V-summary-scrutiny-and-conformity-assessments

 

[Editors' note: This is the sixth article in an ongoing series delving into the MDR and IVDR chapter-by-chapter. The first article focused on the scope and definitionsof the two regulations. The second article and third article explored the MDR and IVDR regulations, respectively, on the topics of making devices available and putting them into service, the obligations of economic operators, reprocessing, CE-marking and free movement. The fourth article focused on Notified Bodies under Chapter IV, and the fifth on conformity assessment procedures under Chapter V. Next up is a look at Chapter VI of the regulations, focusing on clinical evaluation and clinical investigations.



From the editors of Clinica


Read also

  • Biomedtracker: follow the drug development process

    Accurate, Intuitive and Updated In Real Time

    03 Apr 2017

    Learn why pharmaceutical, biotech, and investment companies rely on BioMedTracker for its insight on the likelihood of approval, commercial potential, and future data and regulatory catalysts for drugs within the competitive landscape of every important disease and indication.

  • Biomedtracker: follow the drug development process

    Biomedtracker 2018 Early Outlook Report

    What's on the horizon for pharma in 2018? Find out with Biomedtracker&rsquo;s Early 2018 Outlook Report extract. Download free extracts from this essential report, which investigates the catalysts expected to occur in the first part of the year for 21 different drugs.<br />

    Topics Drug development landscape

  • Scrip: industry news and insights

    Bayer Bets On Oncology Pipeline Vows To Increase 2017 R&D Budget

    By Lucie Ellis 22 Feb 2017

    Bayer has launched an internal oncology R&amp;D unit to speed up development of its pipeline cancer therapies and ensure the company is first to market with its late-stage treatment candidates, head of pharma Dieter Weinand told Scrip on the sidelines of the pharma's annual results conference.

    Topics Cancer

;

Next steps

Whether you’re a small biotech start-up, research firm, generic manufacturer or a global pharmaceutical giant, you need focused, independent insight and opinion on market developments.

Our team is always happy to hear from you. Please call us at:

  • US Toll-Free  : +1 888 670 8900
  • US Toll           : +1 908 547 2200
  • UK & Europe : +44 (20) 337 73737
  • Australia        : +61 2 8705 6907
  • Japan              : +81 3 6273 4260

Or please submit your inquiry via the form so that we can provide you the best possible customer service.

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: